@article{AMJ4692,
author = {John W. Yaxley and Robert A. Gardiner},
title = {The value of routinely combining the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators with multiparametric magnetic resonance imaging to predict clinically significant prostate cancer remains uncertain},
journal = {AME Medical Journal},
volume = {3},
number = {0},
year = {2018},
keywords = {},
abstract = {Multiparametric magnetic resonance imaging (mpMRI) has emerged as a most useful tool for triaging patients with a suspicion of harbouring prostate cancer (PCa). mpMRI findings are ranked by the Prostate Imaging Reporting and Data System (PI-RADS) which has been refined into the current PI-RADs 2 version, this topic having been reviewed recently by Roberts et al. in 2018 (1). mpMRI also has the ability to localise non-palpable cancer within the prostate, which if performed before a prostate biopsy will increase the diagnosis of significant PCa (2-4).},
issn = {2520-0518}, url = {https://amj.amegroups.org/article/view/4692}
}